XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.
The last earnings update was 40 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
XTL Biopharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
XTL Biopharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XTL Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare XTL Biopharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare XTL Biopharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
Unable to compare XTL Biopharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if XTL Biopharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if XTL Biopharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
XTL Biopharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
3/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
XTL Biopharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
XTL Biopharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
XTL Biopharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
XTL Biopharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
XTL Biopharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Joshua Levine, also known as Josh, has been the Chief Executive Officer at XTL Biopharmaceuticals Ltd. since October 15, 2013. Mr. Levine served as the Chief Executive Officer of Proteologics Ltd. since January 2011. He served as a Partner of Neurone Ventures, Neurone Ventures II, L.P., Neurone Funds Management and Platinum Neurone Ventures. Before joining Neurone in June 2000, he spent four years as Managing Director of Corporate Finance for Patterson Travis. Mr. Levine spent seven years as a corporate and reorganization attorney with Willkie Farr & Gallagher. He served as Senior Director of Teva Innovative Ventures (alternate name TEVA Pharmaceutical Industries Ltd.). He worked as an Associate with Wilkie Farr & Gallagher in New York. He has extensive experience in all financial and legal aspects of early stage companies as well as analytical corporate finance experience. From September 2008 to September 2010, he served as Chairman of the Board of Proteologics. He served as Senior Director of Teva Innovative Ventures responsible for, among other things, business development as well as alliance management for the unit. He also held several executive positions within venture capital funds and boutique investment banks. He was a corporate attorney at a large New York City law firm. He served as a Director of XTL Biopharmaceuticals Ltd. and D-Pharm LTD since August 12, 2012. He served as a Director of BOLT Solutions Inc. (alternate name SeaPass Solutions Inc.). Mr. Levine holds a J.D. from Columbia University Law School and a B.A. in Chemistry from Yeshiva University.
Insufficient data for Josh to compare compensation growth.
Josh's remuneration is lower than average for companies of similar size in Germany.
Chief Executive Officer
Chief Financial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the XTL Biopharmaceuticals board of directors is about average.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.